Testosterone Deficiency Clinical Trial
Official title:
Patient Satisfaction After Switching to Oral Testosterone Undecanoate in Men Currently on Testosterone Therapy
Verified date | November 2023 |
Source | University of Miami |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research study is to evaluate patient satisfaction with an oral testosterone agent, Jatenzo, compared to other forms of testosterone therapy.
Status | Completed |
Enrollment | 41 |
Est. completion date | April 6, 2023 |
Est. primary completion date | April 6, 2023 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Voluntarily sign and date the study consent form(s) which have been approved by an Institutional Review Board (IRB). Written consent must be obtained prior to the initiation of any study procedures. 2. Males between 18 and 65 years of age. 3. Documented diagnosis of testosterone deficiency. 4. Prior treatment with testosterone therapy at the time of enrollment with adequate control of low testosterone symptoms. Serum total testosterone < 300 ng/dL on 2 measurements prior to the initiation of testosterone therapy. Patients must have completed an adequate washout period following prior testosterone therapy (4 weeks for gels and injection based therapies and 16 weeks for subcutaneous pellets). 5. Judged to be in good general health as determined by the principal investigator based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). Exclusion Criteria: 1. History of significant sensitivity or allergy to androgens or product excipients. 2. Clinically significant findings in the pre-study examinations including abnormal breast examination requiring follow-up or abnormal ECG. 3. Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or International Prostate Symptom Score (I-PSS) score > 19 points. 4. Body mass index (BMI) = 40 kg/m2. 5. Clinically significant abnormal laboratory value, in the opinion of the investigator, in serum chemistry, hematology, or urinalysis including but not limited to: 1. Baseline hemoglobin > 16 g/dL 2. Hematocrit < 35% or > 50% 6. Poorly controlled blood pressure as defined by Systolic Blood Pressure (SBP) >150 or Diastolic Blood Pressure (DBP) > 90 on two separate measurements 7. Concurrent use of any prohibited medications that can affect testosterone levels or metabolism. 8. History of seizures or convulsions, including febrile, alcohol or drug withdrawal seizures. 9. History of any clinically significant illness, infection, or surgical procedure within 4 weeks prior to study drug administration. 10. History of stroke or myocardial infarction within the past 5 years. 11. History of, or current or suspected, prostate or breast cancer. 12. History of, or current or suspected, pituitary abnormality. 13. History of diagnosed, severe, untreated, obstructive sleep apnea. 14. History of abuse of alcohol or any drug substance in the opinion of the investigator within the previous 2 years. 15. Receipt of any investigational product within 4 weeks or within 5 half-lives prior to the start of treatment. 16. Inability to understand and provide written informed consent for the study. 17. Considered by the investigator or the sponsor-designated physician, for any reason, that the subject is an unsuitable candidate to receive Jatenzo |
Country | Name | City | State |
---|---|---|---|
United States | University of Miami | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Miami | Clarus Therapeutics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient Satisfaction as Measured by TSQM-9 (Global Satisfaction Domain) | Treatment Satisfaction Questionnaire for Medication (TSQM-9) has three domains (Global, Convenience, and Effectiveness), each with a total score ranging from 0 to 100 with the higher score indicating higher patient satisfaction. | Up to 6 months | |
Primary | Hypogonadal Symptoms as Measured by qADAM Questionnaire | Quantitative Androgen Deficiency in the Aging Male (qADAM) has a total score ranges between 10 (most symptomatic) and 50 (least symptomatic). | Up to 6 months | |
Secondary | Serum Testosterone Levels | Serum testosterone levels measured in ng/dL analyzed from peripheral venous puncture blood draw | Up to 6 months | |
Secondary | Serum Estradiol Levels | Serum estradiol levels measured in pg/mL analyzed from peripheral venous puncture blood draw. | Up to 6 months | |
Secondary | Hematocrit Levels | Hematocrit levels measured as a percentage analyzed from peripheral venous puncture blood draw. | Up to 6 months | |
Secondary | PSA Levels Measured in ng/mL | Prostate Specific Antigen (PSA) levels measured in ng/mL analyzed from peripheral venous puncture blood draw. | Up to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03313635 -
Evaluation of Prealbumin Levels in Men With Low-T
|
||
Completed |
NCT03528538 -
The Efficacy of Fenugreek Supplementation on Men's Health
|
N/A | |
Completed |
NCT03091296 -
Diurnal Testosterone Concentration
|
||
Completed |
NCT05019859 -
Effects of a Low Carb Diet on Erectile Function and Serem Testosterone in Men With Metabolic Syndrome
|
N/A | |
Completed |
NCT03282682 -
Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male
|
N/A | |
Terminated |
NCT03335254 -
A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
|
Phase 1/Phase 2 | |
Completed |
NCT00512707 -
Effect of Testosterone in Men With Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT06343870 -
Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)
|
Phase 3 | |
Recruiting |
NCT06177002 -
SARS-CoV-2, TESTOSTERONE AND MALE FRAGILITY
|
||
Recruiting |
NCT05096169 -
Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate
|
Phase 2 | |
Withdrawn |
NCT02082197 -
An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men
|
Phase 3 | |
Completed |
NCT00858650 -
Registry of Hypogonadism in Men
|
N/A | |
Not yet recruiting |
NCT05773183 -
Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
|
||
Withdrawn |
NCT04717362 -
The Effects of Natesto For Treatment Of Hypogonadism
|
Early Phase 1 | |
Not yet recruiting |
NCT04601233 -
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
|
Phase 4 | |
Withdrawn |
NCT04414904 -
Determining the Reproductive Health of Men Post-COVID-19 Infection
|
||
Completed |
NCT01963390 -
Metabolomics During Testosterone Therapy
|
||
Recruiting |
NCT04460872 -
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
|
Phase 2 | |
Not yet recruiting |
NCT04245527 -
Use of Infrared Photomodulation for Hormonal Balance (Joovvin' for Hormonal Health)
|
N/A | |
Completed |
NCT00494208 -
TDSM- Testosterone Dose Response in Surgically Menopausal Women
|
N/A |